Topics

Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More

07:00 EDT 16 Aug 2019 | Xconomy

We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly knew but failed to report it to the FDA before the agency approved Zolgensma in […]

Original Article: Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More

NEXT ARTICLE

More From BioPortfolio on "Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...